# US 2025/0152559 A1 · Methods for treating myc-amplified cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152559 A1
- Document ID: US20250152559A1
- Status: Published application
- Kind: A1
- Application number: 18/944,172
- Filed: 2024-11-12
- Published: 2025-05-15
- Earliest claimed: 2023-11-09
- Assignees: The Governing Council of the University of Toronto; McMaster University
- Applicants: The Governing Council of the University of Toronto; McMaster University
- Inventors: Jason Moffat; Jose Rafael Montenegro Burke; Sheila K. Singh; William D. Gwynne; Chitra Venugopal
- Web page: https://patentgrep.com/patent/US20250152559A1

## CPC

- A61K 31/4196: 1,2,4-Triazoles
- A61P 35/00: Antineoplastic agents
- G01N 33/50: Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing (measuring or testing processes involving enzymes or microorganisms, compositions or test papers therefor; processes for forming such compositions, condition responsive control in microbiological or enzymological processes C12Q)
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates to the treatment of a myc-amplified cancer using a DHODH inhibitor. Also disclosed herein are combination therapies, compositions and kits for the treatment of a myc-amplified cancer comprising a DHODH inhibitor.

## Claims

### Claim 1

A method of treating a myc-amplified cancer comprising administering a dihydroorotate dehydrogenase (DHODH) inhibitor, to a subject in need thereof, wherein the myc-amplified cancer is not acute myeloid leukemia (AML).

### Claim 2 (depends on 1)

The method of claim 1, wherein the myc-amplified cancer is brain cancer, such as MYC-amplified Group 3 medulloblastoma (G3MB), breast cancer, esophageal cancer, lymphoid cancer, myeloid cancer, lung cancer, kidney cancer, ovarian cancer, colorectal cancer or pancreatic cancer, optionally the myc-amplified cancer is a recurrent or a refractory cancer.

### Claim 3 (depends on 1)

The method of claim 1, wherein the DHODH inhibitor is BAY2402234, Brequinar, PTC299, PTC868, or a combination thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein the DHODH inhibitor is BAY2402234.

### Claim 5 (depends on 1)

The method of claim 1, wherein the DHODH inhibitor is administered orally, or directly to the central nervous system, optionally directly to the brain.

### Claim 6 (depends on 1)

The method of claim 1, wherein the DHODH inhibitor is administered at a dose of about 5 mg/kg/day to about 10 mg/kg/day.

### Claim 7 (depends on 1)

The method of claim 1, wherein the DHODH inhibitor is administered as a pharmaceutical composition comprising the DHODH inhibitor and a pharmaceutically acceptable carrier or diluent.

### Claim 8 (depends on 1)

The method of claim 1, wherein the DHODH inhibitor is administered as a combination therapy, optionally the combination therapy includes craniospinal irradiation and/or chemotherapy.

### Claim 9

A method of treating a myc-amplified cancer in a subject comprising administering a dihydroorotate dehydrogenase (DHODH) inhibitor to a subject in need thereof, wherein the myc-amplified cancer has increased pyrimidine and/or purine metabolites relative to a non-cancerous control, wherein the cancer is not acute myeloid leukemia (AML).

### Claim 10 (depends on 9)

The method of claim 9, further comprising, prior to administration,
a) obtaining a biopsy of the myc-amplified cancer; and
b) detecting increased pyrimidine and/or purine metabolites in the biopsy.

### Claim 11 (depends on 9)

The method of claim 9, wherein the pyrimidine metabolites include cytidine-5-monophosphate (CMP), uridine-5-monophosphate (UMP) or both; and/or wherein the purine metabolites include adenosine-5-monophosphate (AMP), guanosine-5-monophosphate (GMP) or both.

### Claim 12 (depends on 9)

The method of claim 9, wherein the myc-amplified cancer is brain cancer, such as MYC-amplified Group 3 medulloblastoma (G3MB), breast cancer, esophageal cancer, lymphoid cancer, myeloid cancer, lung cancer, kidney cancer, ovarian cancer, colorectal cancer or pancreatic cancer, optionally the myc-amplified cancer is a recurrent or a refractory cancer.

### Claim 13 (depends on 9)

The method of claim 9, wherein the DHODH inhibitor is BAY2402234, Brequinar, PTC299, PTC868 or a combination thereof.

### Claim 14 (depends on 9)

The method of claim 9, wherein the DHODH inhibitor is BAY2402234.

### Claim 15 (depends on 9)

The method of claim 9, wherein the DHODH inhibitor is administered orally, or directly to the central nervous system, optionally directly to the brain.

### Claim 16 (depends on 9)

The method of claim 9, wherein the DHODH inhibitor is administered at a dose of about 5 mg/kg/day to about 10 mg/kg/day.

### Claim 17 (depends on 9)

The method of claim 9, wherein the DHODH inhibitor is administered as a pharmaceutical composition comprising the DHODH inhibitor and a pharmaceutically acceptable carrier or diluent.

### Claim 18 (depends on 9)

The method of claim 9, wherein the DHODH inhibitor is administered as a combination therapy, optionally wherein the combination therapy includes craniospinal irradiation and/or chemotherapy.

### Claim 19

A method of selecting a therapy for treating a myc-amplified cancer in a subject comprising:
a) obtaining a biopsy of the myc-amplified cancer;
b) detecting increased pyrimidine and/or purine metabolites in the biopsy; and
c) selecting a dihydroorotate dehydrogenase (DHODH) inhibitor for treating the subject when there is an increased level of pyrimidine and/or purine metabolites in the biopsy, wherein the cancer is not acute myeloid leukemia (AML).

### Claim 20 (depends on 19)

The method of claim 19, wherein the pyrimidine metabolites include cytidine-5-monophosphate (CMP), uridine-5-monophosphate (UMP) or both and/or the purine metabolites include adenosine-5-monophosphate (AMP), guanosine-5-monophosphate (GMP) or both.

### Claim 21 (depends on 19)

The method of claim 19, wherein the myc-amplified cancer is brain cancer, such as MYC-amplified Group 3 medulloblastoma (G3MB), breast cancer, esophageal cancer, lymphoid cancer, myeloid cancer, lung cancer, kidney cancer, ovarian cancer, colorectal cancer or pancreatic cancer, optionally the myc-amplified cancer is a recurrent or a refractory cancer.

### Claim 22 (depends on 19)

The method of claim 19, wherein the DHODH inhibitor is BAY2402234, Brequinar, PTC299, PTC868, or a combination thereof.

### Claim 23 (depends on 19)

The method of claim 19, wherein the DHODH inhibitor is BAY2402234.
